The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
Investigators evaluated patient-reported outcomes and tolerability of capivasertib plus abiterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.
Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real ...
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
A novel scientific method developed at Tel Aviv University promises to accelerate our understanding of the gene PTEN, a key ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results